MedPath

sefulness of using C-11 methionine PET in patient which suspected glioma

Phase 3
Completed
Conditions
glioma
Registration Number
JPRN-jRCTs012180017
Lead Sponsor
Yamaguchi Shigeru
Brief Summary

C-11 methionine-PET will be useful as an additional test for MRI by the following reasons. 1) C-11 methionine-PET detects tumor cells in MRI negative sites with high PPV. 2) In cases which have C-11 methionine-PET test, the rate of without additive effect was low. 3)There was few false negative case.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
72
Inclusion Criteria

(1)The patients whose doctor plans a biopsy or tumor resection and whose tumor is suspected as primary glioma by board-certified diagnostic radiologists and board-certified neurosurgeons based on clinical manifestations, clinical courses, and MRI findings.
(2)The patients who or whose legal representative gave a written informed consent to this study.

Exclusion Criteria

(1)The patients with a history of serious allergic reaction to C-11 methionine or F-18 FDG.
(2)Pregnant women, breast-feeding women, or women who may be pregnant
(3)The patients who is participating in other trials
(4)The patients who underwent C-11 methionine PET within 90 days
(5)The patients whose overall status is not satisfactory for surgical treatment
(6) The patients who cannot undergo contrast-enhanced MRI
(7) The patients whom investigators judged to be inadequate as candidates

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath